Saturday 17 October 2026
Export SILO’s income statement to Excel — free account
Silo Pharma, Inc.
SILO Healthcare Biotechnology
Silo Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $72,100.00, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 73.3% and free cash flow grew 39.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.18
0.02
−1.67%
Follow SILO
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 3 | 3 | — | — | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 3.48 | — | 0.00 | — | — | 0.00 |
Altman Z-Score |
(3.06) | (3.26) | (0.83) | 2.80 | 5.55 | — | 464.42 | — | — | — |
P/S ratio |
39.60 | 45.52 | 65.04 | 97.47 | 190.70 | — | 0.00 | — | — | 0.00 |
Altman Z″-Score (non-manufacturers) |
(1.23) | (3.93) | 2.06 | 10.51 | 10.09 | — | (25.23) | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — | 0.00 |
P/Operating CF |
(3.65) | (3.57) | (5.15) | (7.92) | (17.54) | — | (1,403.41) | — | — | 0.00 |
P/B ratio |
0.45 | 0.65 | 0.76 | 0.68 | 1.50 | — | 0.00 | — | — | 0.00 |
Price to Tangible BV |
0.47 | 0.68 | 0.76 | 0.68 | 1.50 | — | 0.00 | — | — | 0.00 |
EV/Sales |
(55.61) | (52.77) | (41.37) | (60.40) | 46.69 | — | 0.00 | — | — | 0.00 |
EV/EBITDA |
0.94 | 0.81 | 0.79 | 1.20 | 0.00 | — | 0.00 | — | — | 0.00 |
EV/Operating CF |
0.86 | 0.99 | 0.92 | 1.24 | (1.46) | — | (517.26) | — | — | 0.00 |
EV/FCF |
0.86 | 0.99 | 0.92 | 1.24 | (1.46) | — | (517.26) | — | — | 0.00 |
Quick Ratio |
10.55 | 4.28 | 9.88 | 26.06 | 20.93 | 7.96 | 1.04 | 11.77 | 42.16 | 23.97 |
Current Ratio |
11.36 | 4.29 | 9.90 | 26.52 | 21.23 | 10.07 | 4.23 | 13.04 | 42.86 | 24.47 |
Net Debt/EBITDA |
1.61 | 1.51 | 2.04 | 3.13 | 3.89 | 0.83 | 0.07 | 0.94 | 3.29 | 3.08 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.29% | 12.54% | 2.61% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (2.70) | 0.05 | 0.00 | 0.00 |
Asset Turnover |
0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.06 | 0.00 | 0.00 | 0.08 |
Operating CF/Net income |
1.10 | 0.87 | 0.87 | 0.89 | (0.91) | 0.37 | 0.78 | (0.28) | (0.80) | 0.13 |
Capex/Depreciation |
(50.43) | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Interest Coverage |
(114.76) | (922.69) | (786.86) | (1,648.95) | (914.77) | (8.18) | (14.79) | (141.48) | — | — |
| (74.56%) | (78.37%) | (44.81%) | (40.29%) | 48.34% | (493.96%) | (527.07%) | (120.40%) | 34.79% | 0.00% | |
| (56.31%) | (57.96%) | (38.17%) | (35.32%) | 41.95% | (323.51%) | (150.21%) | (77.66%) | 24.24% | (171.28%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (880.40%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(62.75%) | (80.52%) | (53.59%) | (35.10%) | 25.22% | (241.75%) | (268.71%) | (167.73%) | 22.24% | (89.29%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 428.77 |
Research and Development Expense of Revenue |
2,996.95% | 3,284.60% | 1,172.12% | 1,784.19% | 973.21% | 0.00% | 156.40% | — | — | 0.00% |
Selling, General and Administrative Expense of Revenue |
2,978.64% | 3,333.98% | 4,267.41% | 3,366.85% | 3,177.00% | 0.00% | 2,128.57% | 0.00% | 0.00% | 883.73% |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
881.00% | 0.00% | 19.56% | 216.37% | 117.39% | 0.00% | 438.42% | — | — | 0.00% |
Graham Net Nets |
2.14 | 1.44 | 1.31 | 1.46 | 0.66 | — | 0.00 | — | — | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 222.90 | — | 0.46 | — | — | 0.00 |
Earnings Yield |
(158.75%) | (137.01%) | (78.86%) | (55.71%) | 28.76% | — | (0.25%) | — | — | (0.04%) |
Free Cash Flow Yield |
(163.47%) | (116.98%) | (68.85%) | (49.84%) | (16.78%) | — | (0.19%) | — | — | (0.25%) |
Revenue per Share |
0.13 | 0.29 | 0.35 | 0.47 | 0.56 | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(8.34) | (15.62) | (15.70) | (22.95) | (17.99) | (0.26) | (0.51) | 0.08 | (0.09) | 0.00 |
Capex per Share |
(1.03) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Free Cash Flow per Share |
(9.37) | (15.62) | (15.70) | (22.95) | (17.99) | (0.26) | (0.51) | 0.08 | (0.09) | 0.00 |
Cash per Share |
12.27 | 28.84 | 37.32 | 74.61 | 81.02 | 0.26 | 0.08 | 0.17 | 0.48 | 0.00 |
Shareholders Equity per Share |
11.28 | 20.51 | 30.07 | 67.85 | 71.58 | 0.29 | (0.01) | 0.12 | 0.36 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
11.28 | 20.51 | 30.07 | 67.85 | 71.58 | 0.29 | (0.01) | 0.12 | 0.36 | 0.00 |
Free Cash Flow |
(5.24) | (3.83) | (3.22) | (3.50) | (2.28) | (1.16) | (0.79) | 0.27 | (0.28) | (0.14) |
Working Capital |
6.74 | 5.46 | 6.91 | 11.14 | 9.91 | 1.29 | 0.38 | 0.58 | 1.60 | 1.25 |
Capital Expenditures |
(0.57) | — | — | — | — | — | — | — | — | — |
Net Current Asset Value |
6.09 | 4.73 | 6.11 | 10.27 | 8.97 | 1.28 | (0.02) | 0.18 | 1.20 | 0.85 |
EV/EBIT |
0.94 | 0.81 | 0.77 | 1.20 | 0.00 | — | 0.00 | — | — | 0.00 |
Capex to Sales |
7.97 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Cash ROIC |
(39.78%) | (31.65%) | (23.29%) | (16.11%) | (11.79%) | (47.94%) | (496.13%) | 27.41% | (10.10%) | (6.97%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 1.61 | 0.00 | 0.00 | 0.31 | — | — | 0.00 |
Accounts Payable Turnover |
0.04 | 0.01 | 0.01 | 0.01 | 0.02 | 0.00 | 0.68 | 0.55 | 0.00 | — |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.30 | 0.00 | — | — |
Average Days of Payables |
4,763.13 | 99,676.47 | 44,271.98 | 22,919.48 | 30,506.70 | 0.00 | 731.33 | 530.91 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 2,083.43 | 559.94 | — | — |
Average Receivables |
— | — | — | 0.04 | — | 0.11 | 0.13 | — | — | — |
Average Payables |
1.08 | 1.14 | 0.53 | 0.39 | 0.27 | 0.09 | 0.04 | 0.03 | 0.05 | — |
Average Inventory |
— | — | — | — | — | — | 0.09 | — | — | — |
Average Assets |
7.51 | 7.58 | 9.69 | 11.07 | 5.96 | 0.96 | 0.67 | 1.25 | 1.47 | 0.65 |
Average Common Equity |
5.67 | 5.61 | 8.26 | 9.70 | 5.17 | 0.63 | 0.19 | 0.81 | 1.02 | — |
Columns are period end dates